Gyre Therapeutics, Inc. Impairment of Intangible Assets (Excluding Goodwill)
Gyre Therapeutics, Inc. (GYRE) reported Impairment of Intangible Assets (Excluding Goodwill) of $89.00 thousand for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2016-03-09
- Gyre Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2015-03-31 was $89.00K.
- Gyre Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2014 was $53.00K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month as first filed |
|---|---|---|---|
| 2015-03-31 | $89.00K 10-Q · filed 2015-05-07 | ||
| 2014-12-31 | $53.00K 10-K · filed 2016-03-09 | $89.00K 10-Q · filed 2015-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |